| 1 |
33771885 | Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. | 2021 Jun |
2 |
| 2 |
33990090 | Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study. | 2021 May 14 |
1 |
| 3 |
34743450 | [Clinical features and prognostic value of TP53 mutation in Chinese prostate cancer patients]. | 2021 Nov 1 |
4 |
| 4 |
31822380 | TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. | 2020 Apr |
1 |
| 5 |
30209161 | TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. | 2019 Mar 15 |
1 |
| 6 |
31046065 | Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. | 2019 Jul 1 |
1 |
| 7 |
29302046 | p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. | 2018 Jun |
1 |
| 8 |
28411207 | Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. | 2017 Jul |
1 |